Home › Intestinal Cancer › NCT07845617
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma: A Prospective Feasibility Study
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18-80 years * Histologically confirmed pancreatic or duodenal adenocarcinoma * Completed or currently receiving curative-intent treatment * Evidence of isolated or liver-dominant metastases (radiographic or clinical) * Deemed clinically eligible for hepatic artery infusion pump (HAIP) placement and floxuridine (FUDR)-based chemotherapy by a multidisciplinary oncology team * Scheduled for HAIP placement at AdventHealth Orlando Exclusion Criteria: \- Patients who are clinically ineligible for HAIP placement or FUDR therapy are excluded
About the study
The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant metastases after surgery and systemic chemotherapy. The main questions it aims to answer are:
Does HAIP chemotherapy improve liver tumor response based on imaging criteria (RECIST)? What are the progression-free survival and overall survival outcomes in this patient population?
Participants will:
Undergo placement of a hepatic artery infusion pump as part of standard clinical care Receive floxuridine (FUDR)-based chemotherapy through the pump Have clinical data, imaging results, and laboratory markers (e.g., ctDNA, CEA, CA 19-9) collected from their medical records over time
What is being tested
- Hepatic Artery Infusion Pump (HAIP) (device)
- Floxuridine (FUDR) (drug)
Sponsor: AdventHealth · Participants: 10 · Started: Nov 1, 2026
Contact the study team
- Maggie Polanco, RN · Phone: 407-303-7381
Official record on ClinicalTrials.gov — NCT07845617
Locations in the U.S.
| Florida | AdventHealth Orlando, Orlando |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.